Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250016/S004

Belotero Intense (+) Lidocaine

Merz North America, Inc. · Decision date Aug 31, 2026

FDA DECISIONP250016/S004

What did the FDA approve?

FDA records P250016/S004 as a supplement to PMA P250016, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Aug 31, 2026.

FDA approval order statement

approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250016.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
General, Plastic Surgery
Decision date
Aug 31, 2026
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P250016/S004
Regulatory pathway
PMA supplement
Product code
LMH
Decision code
APPR
Decision date
Aug 31, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Product code
LMH
FDA device class
3

For the original device and its historical approval scope, see PMA P250016. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250016 · Original PMA

    Belotero Intense (+) Lidocaine

  2. P250016/S002 · Related supplement

    Belotero Intense (+) Lidocaine

  3. P250016/S004 received

    Application receipt date recorded by FDA.

  4. P250016/S001 · Related supplement

    Belotero Intense (+) Lidocaine

  5. P250016/S004 · FDA decision

    Normal 180 Day Track No User Fee

  6. P250016/S006 · Related supplement

    Belotero Intense (+) Lidocaine Dermal Filler

Timeline entries are records held by MedtechLedger for P250016. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250016

Product / regulatory recordCompanyPathwayDecision dateSource
Merz North America, Inc.PMA approvalJul 9, 2026FDA
Merz North America, Inc.PMA supplementJul 31, 2026FDA
Merz North America, Inc.PMA supplementAug 5, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementNov 4, 2026FDA
Prollenium Medical Technologies, Inc.PMA supplementOct 14, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA
saypha ChiQP250021/S001
Croma-Pharma GmbHPMA supplementOct 7, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Merz North America, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6501 Six Forks Rd., Raleigh, NC, 27615

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records